Summary:
- Kinvard Bio Inc, a biotechnology company in Raleigh, NC, has received $2.7M in funding from CARB-X to advance their OPP program targeting serious bacterial infections.
- The company is developing a new class of antibiotics called oxepanoprolinamides (OPPs) that show broad-spectrum activity against resistant bacteria.
- Kinvard Bio aims to address the high unmet medical need for effective treatments for lower respiratory tract infections, skin and soft tissue infections, and other bacterial diseases.
Article:
Kinvard Bio Inc Secures $2.7M Funding for Innovative Antibiotics Development
Kinvard Bio Inc, a biotechnology company based in Raleigh, North Carolina, has recently announced a significant milestone in their mission to combat antibiotic-resistant bacteria. The company has received $2.7M in follow-on non-dilutive funding from CARB-X, a clear indicator of the potential impact of their innovative approach to antibiotic development.
The funding will be utilized to accelerate the advancement of Kinvard Bio’s Oxepanoprolinamides (OPPs) program, which targets high-priority pathogens responsible for serious lower respiratory tract infections (LRTIs) and skin and soft tissue infections (SSTIs). OPPs represent a new class of antibiotics that demonstrate broad-spectrum activity against multidrug-resistant Gram-positive and Gram-negative bacteria, as well as nontuberculous mycobacteria.
Kinvard Bio is actively building a pipeline of oral and intravenous small molecule antibiotics to address the urgent medical need for effective treatments for bacterial pneumonia, complicated urinary tract infections (cUTI), and nontuberculous mycobacterial lung disease (NTM-LD). By focusing on overcoming resistance mechanisms that compromise standard-of-care antibiotics, the company is positioned to make a significant impact in the fight against antibiotic-resistant infections.
In conclusion, Kinvard Bio’s commitment to advancing innovative antibiotics through their OPP program showcases their dedication to addressing the growing threat of antibiotic resistance. With the support of CARB-X funding, the company is well-positioned to continue making strides in developing effective treatments for serious bacterial infections.
